Predictors of Severe COVID-19 Outcomes (PRESCO)

Verily Life Sciences

Status: Completed

Conditions: COVID-19; Acute Respiratory Distress Syndrome

Study type: Observational

Funder types: Industry

Identifiers

NCT04388813

102293

Details and patient eligibility

About

This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.

Enrollment: 494 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant or legally authorized representative willing and able to provide informed consent
• Receiving care at a participating site
• Age 18 years old or older
• U.S. Resident
• Confirmed positive for COVID-19
• Willing and able to comply with all study procedures

Exclusion criteria

• Self reported pregnancy